bpc-157 human clinical trial osteoarthritis For Knee Pain: Early Reported Outcomes, A report on intra-articular BPC-157 for knee pain described high rates of improvement: ~92% with BPC-157 alone, ~75% when combined with thymosin beta-4, Peptide Therapy 101: Can BPC-157
Description
Cisplatin was administered intravenously at a dose of 75 mg/m2 approximately 30 minutes after ALIMTA administration on Day 1 of each cycle, gemcitabine was administered at a dose of 1250 mg/m2 on Day 1 and Day 8, and cisplatin was administered intravenously at a dose of 75 mg/m2 approximately 30 minutes after administration of gemcitabine, on Day 1 of each 21-day cycle
&srotate=0)
Clinical data shows that starting at 2mg instead of 4mg significantly reduces GI symptom frequency and intensity

You will enjoy your visit to Skin and Tonic

10.1038/aps.2017.12 163 LuoL.GongJ.WangZ.LiuY.CaoJ.QinJ.et al (2022)

Many protocols start at the lower end and adjust based on the specific research objectives

I know you do
